In vitro, ARQ 531 suppresses BTK-dependent functions including BCR signaling and transcription of NF-κB genes, thereby suppressing viability, cell activation, and migration of primary CLL cells [55]. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.